Replies to post #240314 on Biotech Values

[DewDiligence]

NLTX—I’m unclear about whether the drug in the abstract, which is an antagonist of IL-2/15, is the company’s lead compound. I presume that it is not the same drug that was described in NLTX's capsule summary at the time of the 2019 reverse-merger (#msg-150347293):

Neoleukin’s lead product candidate, NL-201, is a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin-2 and interleukin-15 for the treatment of various types of cancer by activating both T-cells and NK-cells to fight cancer, while limiting toxicity with minimal loss of activity.

I.e. NL-201 is (was) for cancer, not autoimmune conditions.